205 related articles for article (PubMed ID: 34743447)
1. [Immunotherapy for locally advanced or metastatic urothelial carcinoma: research advances and perspectives].
Ai K; Li Y
Zhonghua Wai Ke Za Zhi; 2021 Nov; 59(11):881-885. PubMed ID: 34743447
[TBL] [Abstract][Full Text] [Related]
2. Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma.
Sano T; Saito R; Aizawa R; Watanabe T; Murakami K; Kita Y; Masui K; Goto T; Mizowaki T; Kobayashi T
Int J Clin Oncol; 2023 Dec; 28(12):1573-1584. PubMed ID: 37874429
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
5. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.
Rizzo A; Mollica V; Santoni M; Ricci AD; Gadaleta-Caldarola G; Montironi R; Massari F
Future Oncol; 2022 Feb; 18(6):739-748. PubMed ID: 35048736
[No Abstract] [Full Text] [Related]
6. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
Hui G; Stefanoudakis D; Zektser Y; Isaacs DJ; Hannigan C; Pantuck AJ; Drakaki A
Curr Oncol; 2023 Aug; 30(8):7398-7411. PubMed ID: 37623017
[TBL] [Abstract][Full Text] [Related]
7. Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy.
You X; Zhu C; Yu P; Wang X; Wang Y; Wang J; Yu J; Wang K
Biomed Pharmacother; 2024 Feb; 171():116152. PubMed ID: 38228034
[TBL] [Abstract][Full Text] [Related]
8. Updates and novel treatments in urothelial carcinoma.
Hanna KS
J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy in advanced urothelial cancer].
Géczi L; Dienes T; Küronya Z; Maráz A; Nagyiványi K
Magy Onkol; 2021 Dec; 65(4):339-346. PubMed ID: 34874365
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab for the treatment of bladder cancer.
Sundahl N; Rottey S; De Maeseneer D; Ost P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for metastatic urothelial carcinoma.
Lalani AA; Sonpavde GP
Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
[TBL] [Abstract][Full Text] [Related]
13. First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis.
Parikh RB; Feld EK; Galsky MD; Adamson BJ; Cohen AB; Baxi SS; Boursi SB; Christodouleas JP; Vaughn DJ; Meropol NJ; Mamtani R
Future Oncol; 2020 Jan; 16(2):4341-4345. PubMed ID: 31840537
[No Abstract] [Full Text] [Related]
14. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
Giridhar KV; Kohli M
Mayo Clin Proc; 2017 Oct; 92(10):1564-1582. PubMed ID: 28982487
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab in urothelial cancers.
Lavaud P; Hamilou Z; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
[TBL] [Abstract][Full Text] [Related]
19. Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies.
Grivas P; Huber C; Pawar V; Roach M; May SG; Desai I; Chang J; Bharmal M
Clin Genitourin Cancer; 2022 Apr; 20(2):114-122. PubMed ID: 34903481
[TBL] [Abstract][Full Text] [Related]
20. [Systemic treatment of bladder cancer].
Haas M; Burger M; Schnabel MJ
Urologe A; 2021 Sep; 60(9):1167-1174. PubMed ID: 34043031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
